Welcome, Guest. Please login or register.
May 27, 2024, 09:19:10 pm

Login with username, password and session length

  • Total Posts: 773605
  • Total Topics: 66391
  • Online Today: 315
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 3
Guests: 281
Total: 284


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: MONCAY study - Dolutegravir monotherapy  (Read 4234 times)

0 Members and 1 Guest are viewing this topic.

Offline Jim Allen

  • Administrator
  • Member
  • Posts: 22,507
  • Threads: @jim16309
    • Social Media: Threads
MONCAY study - Dolutegravir monotherapy
« on: August 31, 2018, 06:24:28 pm »
So previously the dutch "DOLUMONO" study that looked at dolutegravir monotherapy failed, with lower suppression rates & resistance:

Seems now a similar fate with a french dolutegravir monotherapy study

August 31, 2018

Switching people with HIV from a three-drug antiretroviral (ARV) regimen to treatment with Tivicay (dolutegravir) alone raises the risk of viral rebound to an unacceptable extent, aidsmap reports. Consequently, researchers have argued that switching individuals to Tivicay monotherapy—treating the virus with just that ARV, instead of with standard combination therapy—is unethical because of safety concerns.

Presenting their findings at the International AIDS Conference in Amsterdam (AIDS 2018), French researchers from the MONCAY study enrolled 158 HIV-positive adults with a fully suppressed viral load thanks to Triumeq (dolutegravir/abacavir/lamivudine) treatment who had never had an AIDS-defining illness or a lowest-ever CD4 count below 100.

The participants were randomized to remain on triple-drug treatment with Triumeq or to receive Tivicay monotherapy—a respective 80 and 78 participants were put on each treatment.

The study looked primarily at the difference in viral suppression rates between the two groups after 24 weeks of treatment: 96 percent of those on Triumeq had a viral load below 50 at this point, compared with 94 percent of those on Tivicay monotherapy. By this point in the study, two of those on monotherapy had experienced virological rebound—meaning a viral load above 50—compared with no one in the triple-drug therapy group.

After an additional 24 weeks of treatment, another five members of the monotherapy group experienced virologic rebound; two of them developed new viral mutations associated with resistance to integrase inhibitors. (Tivicay belongs to that class of ARVs.) This led the study’s data and safety monitoring board to stop the study.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

My Instagram

Offline CaveyUK

  • Global Moderator
  • Member
  • Posts: 1,642
Re: MONCAY study - Dolutegravir monotherapy
« Reply #1 on: September 01, 2018, 07:35:17 am »
Fully understand why they would stop this study, but I suppose the interesting aspect of this is that for only 2% viral rebound after 6 months, and 10% after 12 months (so after a year on mono therapy 90% of people were still UD) there is scope to suggest that DTG isn't that far from being effective on it's own, which would suggest that it may not take a particularly powerful second agent - or a refinement to DTG to bridge that gap, which bodes well in terms of future drug development and the simplification of regimens ultimately.

HIV - Basics
HIV 101
You can read more about Transmission and Risks here:
HIV Transmission and Risks
You can read more about Testing here:
HIV Testing
You can read more about Treatment-as-Prevention (TasP) here:
You can read more about HIV prevention here:
HIV prevention
You can read more about PEP and PrEP here:
PEP and PrEP

Offline Mindless

  • Member
  • Posts: 362
Re: MONCAY study - Dolutegravir monotherapy
« Reply #2 on: September 01, 2018, 08:55:00 am »
which would suggest that it may not take a particularly powerful second agent

You mean something like Juluca? Or another kind of solution?
Dx Feb. 2018, CD 320, %14

- Atripla Feb/18 -->
- Complera (generic) 2019 -->
- Dovato (generic) 2021 -->


Terms of Membership for these forums

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.